PMC1 CORRECTING AN UNDERESTIMATE OF INCREMENTAL COST EFFECTIVENESS RATIO CONSIDERING STATISTICAL ERRORS AND PROBABILITY OF TRUTH  by Kamae, I et al.
A386 Paris Abstracts
18.6 UI/KG (14.2–19.6) for patients undergoing urgent surgery, 22.3 UI/KG (19.2–24, 
n: 41) for patients with overdose. In 66%, a risk factor of overdose was identiﬁed: 
age 75 years (63%), comorbidity (15% like diabetes). The median cost of PCC 
treatment was a888/patient (a592–a888) representing 9.3% of the total hospitalisa-
tion cost paid by national health insurance for those 91 patients. CONCLUSIONS: 
PCC was used according to the recommendations and in respect of the health care 
regulations for reimbursement. The high increase of prescription observed in 2008, 
mainly in the emergency department (48%), can be explained by a change of medical 
practices and prescribing behaviour since the new recommendations.
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OBJECTIVES: According to WHO data approximately 1.6 billion adults are over-
weight with at least 400 million being obese (BMI  30). In Western Europe up to 
4% of total expenditures on health care are spent on managing obesity and obesity 
dependent chronic diseases including diabetes, cardiovascular diseases and cancer. The 
aim of this systematic review was to ﬁnd studies on direct cost estimates of obesity 
and its comorbidities in Poland. METHODS: Search and selection of data was based 
on a protocol developed before proceeding with the search and compilation of data. 
Two researchers independently assessed publications according to pre-deﬁned inclu-
sion criteria and with regard to study methodology. The review covered following 
databases: MEDLINE, EMBASE and PBL (Polish Medical Bibliography). Last update 
of the search results have been made on May 10, 2009. RESULTS: In the result of 
the systematic review only 2 studies were found: Szponar et al. 2006 and Krzyza-
nowska et al. 2008. In those studies direct costs of treating obesity and associated 
diseases have been estimated at between 20 to 30% of the total health care expendi-
tures in Poland. Based on OECD data it gives the amount of 8.15 to 12.2 billion USD 
according to PPP in 2008. CONCLUSIONS: Economic burden of obesity and its 
comorbidities in Poland is undoubtedly signiﬁcant. In 4 European countries with 
obesity prevalence similar to Poland (Portugal, Norway, Belgium and Sweden), the 
cost of treating obesity and associated diseases has been estimated on average at 
0.32% GDP. If the cost of obesity and its comorbidities in Poland amounted also to 
0.32% of GDP, the total burden of disease could have been estimated at 1.95 billion 
USD. We conclude that speciﬁc Polish data from the two above mentioned studies can 
be signiﬁcantly overestimated and there is an urgent need for further research in order 
to estimate the true value of these costs.
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Tomek D1, Bielik J2
1Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, 2Trencin University, 
Trencin, Slovak Republic
OBJECTIVES: Although health spending is well below the OECD average when con-
sidered as a share of GDP, Slovakias pharmaceutical expenditures accounts 32% of 
total health care budget. The accessibility and availability of innovative drugs is good. 
Mandatory HTA (pharmacoeconomy) is incorporated in all relevant legislation, MoH 
set the ofﬁcial threshold by l1  a18,000/QALY and l2  a26,500/QALY. METHODS: 
We have analysed the legislation and ofﬁcial reimbursement decisions and commentar-
ies, published by the MoH in 2009. We analysed the applicants documentation 
including pharmacoeconomic analysis, as a mandatory part of the application. 
RESULTS: The main drug reimbursement body—Categorisation committee of the 
MoH and pharmacoeconomic advisory committee evaluated the applicants dossier for 
the biologic drug ustekinumb (Stelara®, Jannssen Cilag Slovakia) for the treatment of 
psoriasis. The pharmacoeconomic part of the application fulﬁled all legislative aspects. 
The CEA shows that ustekinumab is more cost effective in cost of theraphy responder 
analysis vs. other biologics in the Slovak market for psoriasis treatment by 2%—60%. 
The price sensitivity analysis of comparators was done. The reassessment of CEA after 
massive price cut of comparators (up to 32%, due to international price referencing) 
has showed the positive results for ustekinumab and robustness of previous price 
sensitivity analysis. CONCLUSIONS: The focus of the MoH drug policy is on more 
rational spendings , especially on reference pricing and HTA. There are ﬁrst results 
of these new procedures, where the real impact of the HTA in the decision processes 
is demonstrated. Ustekinumb a new agent in therapy of psoriasis fulﬁlled the necessary 
legislative conditions including pharamacoeconomic aspects to be listed in the positive 
reimbursement list.
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OBJECTIVES: To describe the prescription pattern of rimonabant in relation to the 
approved indications and the stated limitations of reimbursement. Secondly to 
compare the efﬁciency and adverse effects in rimonabant treated patients with the 
impact of conventional care in matched controls without rimonabant treatment during 
a follow up period of up to 12 months. METHODS: The survey was based on retro-
spective collection of data through a speciﬁed extraction and data management 
method, Pygargus Customized eXtraction Program (CXP) developed to extract patient 
data from an Electronic Health Record (EHR) system (Profdoc Journal III). Centers 
were selected with a wide socio-economic and geographical spread. RESULTS: Body 
mass index (BMI) was available in 922 patients out of 1477 (62%). Of those patients, 
93% were prescribed rimonabant according to the indication and 79% within the 
reimbursement criteria. In reality, 97% of the total cohort obtained reimbursement. 
Patients prescribed rimonabant for at least 6 months showed a mean weight reduction 
of 6.0 kg after 12 months compared to 0.4 kg in controls. The mean decrease in 
HbA1c was 0.3% in patients with type-2 diabetes versus 0.0% in controls. More than 
half of patients and controls (54.4 vs. 54.3 %) had a documented psychiatric illness 
such as anxiety, depressive disorders or sleep disturbances at baseline. There was no 
increase in the co-prescription of anxiolytics /sedatives /anti-depressant over time 
comparing rimonabant treated patients with controls. CONCLUSIONS: The majority 
of patients were prescribed rimonabant according to the given rules for indication and 
reimbursement. Weight reduction in the total cohort and reduction of HbA1c in 
patients with type 2 diabetes during the follow up year, were of similar magnitude as 
reported in various clinical trials. The safety analysis did not signal any increase in 
adverse events including psychiatric illness in patients treated with rimonabant more 
than six months.
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OBJECTIVES: To review recommendations of Health Technology Assessment (HTA) 
reports on sibutramine and orlistat in the treatment of obesity from France (HAS), 
UK (NICE), Sweden (TLV), Belgium (KCE) and Canada (CADTH). METHODS: HTA 
reports were identiﬁed by searching each HTA agency’s homepages using “sibu-
tramine” OR “orlistat” as keywords. Results were categorised as Recommended, 
Restricted recommended and Not Recommended in comparison to the indication for 
marketing authorisation given by EMEA. RESULTS: A total of eleven HTA reports 
were identiﬁed; six assessing orlistat and ﬁve sibutramine. Four HTA-reports on orli-
stat gave a positive recommendation while the remaining HTA reports did not recom-
mend use/funding. Reasons for not recommending orlistat included; insufﬁcient data 
to quantify obesity-related morbidity and mortality, uncertainties in compliance due 
to side effects, treatment effect was not maintained after discontinuation, lack of long 
term safety data, and poor deﬁnition of indication “metabolic syndrome”. For sibu-
tramine, three reports concluded Recommended, one Restricted recommended and 
one Not recommended. Reasons for a negative and restricted recommendation 
included; insufﬁcient data to quantify obesity-related morbidity and mortality, and 
lack of long term safety data. CONCLUSIONS: Quantity of effect of weight loss on 
morbidity and mortality, deﬁning an appropriate indication for initiating pharmaco-
logical treatment and adequate provision of data on long-term safety and effectiveness 
appears to be main issues driving a negative recommendation. These issues must be 
addressed in the development of a clinical documentation of future pharmacological 
treatments of obesity. It is interesting to notice that similar evidences lead to very           
contradictory outcome reﬂecting broader way to scrutinize evidences for HTA decision 
making.
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OBJECTIVES: To clarify how the standard estimate of incremental cost-effectiveness 
ratio (ICER) theoretically changes, affected by the uncertainty accompanied with sta-
tistical errors and probability of truth in evidence-based practice, and further to 
investigate how the ‘risk’-adjusted ICER (r-ICER) could be used in the analysis of 
efﬁciency frontier by IQWiG. METHODS: A decision analysis was performed using: 
1) probability of truth, 1 – p, for a null hypothesis (or p for the alternative hypothesis), 
2) type I error (A), and 3) type II error (B).The decision tree modeled a patient facing 
the alternative decisions for treatment: evidence-based (Teb) or conventional (Tc), 
considering the choices: 1) Tc: if no evidence available about a new treatment A, then 
the patient takes a conventional treatment B, and 2) Teb: if positive evidence of a 
clinical trial available, then take the treatment A, whereas if the evidence is negative, 
take the treatment B. Given a pair of beneﬁt and cost for the treatments A and B, 
respectively noted as (Ea, Ca) and (Eb, Cb) at the terminal node, then the operations 
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of folding-back and averaging-out were repeatedly applied until the expected values 
of beneﬁt and cost are eventually calculated at the ﬁrst decision-node. RESULTS: 
Comparing Teb to Tc, we obtained the incremental cost and beneﬁt for (p(1-B)  
A(1-p))(Ca – Cb) and p(1-B)(Ea – Eb), respectively. Then, dividing the former by the 
latter resulted in the formula: r-ICER  (1k) x ICER, where k  (A(1-p))/((1-B)p). It 
implies that the risk-adjustment corrects the underestimation of ICER since k takes a 
positive value. Hence, the efﬁciency frontier deﬁned by a series of r-ICERs transformed 
into an inferior position, compared to the original one. CONCLUSIONS: The r-ICER 
can correct an underestimate of the standard ICER and will be useful in risk-sensitive 
evaluation using ICERs including the efﬁciency frontier.
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TRADITIONAL OUTCOME MEASURES FOR USE IN HEALTH CARE 
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Badia X1, Vieta A1, Sacristán JA2
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OBJECTIVES: Non-traditional outcomes (NTOs), those related with patient reported 
outcomes (PROs), economic and non-traditional clinical outcomes, are frequently 
being used to assess health interventions. We propose a standardized approach to 
assess the utility of NTO measures for use in health care decision making. METHODS: 
A systematic review of NTOs in Type 2 Diabetes Mellitus (T2DM) was conducted. 
Inclusion and exclusion criteria, data sources, search strategy, and data extraction and 
quality assessment of the studies and NTOs were deﬁned. The degree of recommenda-
tion of each NTOs was based on the quality of the outcome and the scientiﬁc evidence 
to support it. Two independent reviewers carried out each activity. RESULTS: NTOs’ 
were assessed within a three-grade quality scale in terms of feasibility, validity, sensi-
tivity, reliability, comparability and understanding. NTOs were categorized as key, 
important, and with not enough evidence to support its use in health decision-making. 
Case study in T2DM: 3805 citations and 235 potentially eligible full articles were 
retrieved and 153 studies met the inclusion criteria. Eighty-eight (5 clinical, 54 human-
istic and 29 economic) NTOs in T2DM were retrieved. A total of 21.6% of the NTOs 
were considered key, 36.4% important and for 42% not enough evidence was found 
to support its use in T2DM. CONCLUSIONS: An evidence based understanding of 
NTOs’ validity to measure treatment outcomes in different conditions is needed since 
clinicians and payers may use them for decision-making purposes.
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OF ORAL TRIPTANS IN THE MANAGEMENT OF ACUTE MIGRAINE: 
DIFFERENT MEASURES OF EFFICACY EXTRACTED FROM THE SAME 
META-ANALYSIS
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OBJECTIVES: Meta-analyses are recommended and frequently utilized in cost-effec- 
tiveness analyses. The aim of this study was to assess if efﬁcacy data obtained from              
one meta-analysis is used differently in various cost-effectiveness analyses of oral anti-
migraine medications (triptans). METHODS: A literature review was conducted in 
order to identify studies, assessing the cost-effectiveness of triptans, that used the 
meta-analysis by Ferrari et al. (2002) as the primary source of efﬁcacy. Studies were 
included in the literature review if they assessed the cost-effectiveness of two or more 
triptans (almotriptan, eletriptan, frovatriptan, naratriptan, sumatriptan, rizatriptan or 
zolmitriptan) in the adult population using an average or incremental cost-effectiveness 
ratio as an outcome measure. RESULTS: In total, 12 studies were included in the ﬁnal 
review. Five different measures of efﬁcacy were used in the reviewed studies. These 
were “sustained pain free with no adverse effects” (n  6), “24 hour sustained response” 
(n  3), “sustained pain free” (n  4), “pain free at two hours” (n  1), and “quality 
adjusted life year” (QALY) (n  2). In addition, four alternative methods were used 
to calculate the “sustained pain free with no adverse effects”. In total, this resulted in 
eight alternative measures of efﬁcacy derived from a single meta-analysis. CONCLU-
SIONS: The choice of efﬁcacy measure can differ between different cost-effectiveness 
studies, even those based on same literature source. This may affect the applicability 
of the cost-effectiveness analysis in decision making. However, the underlying reasons 
for the variation in the choice of efﬁcacy measure, and the association between choice 
of efﬁcacy measure and the study conclusion need thorough research. Therefore, there 
is still room for conventional one-way sensitivity analyses that enable evaluation of 
the effects of “qualitative” data source uncertainties on the study results.
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LARGELY IGNORED: THE IMPACT OF THE THRESHOLD VALUE FOR A 
QALY ON THE IMPORTANCE OF A TRANSFERABILITY FACTOR
Vemer P, Rutten-van Molken M
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Recently, several checklists have been developed which systematically check the trans-
ferability of cost-effectiveness (CE) studies between jurisdictions. Some even provide 
a quantitative score of the degree of transferability. The interpretation of such a score 
is, however, difﬁcult. In addition, the threshold value for a QALY is a factor that has 
been given little consideration in these checklists. The importance of a factor as a 
cause of between-country differences in CE depends on this threshold: factors that 
explain most of the differences in CE at a low threshold need not be the same factors 
at a higher threshold. OBJECTIVES: To compare the impact of nine potential causes 
of variation in CE of smoking cessation support (SCS), at different thresholds for the 
willingness-to-pay per QALY (WTP). METHODS: A model-based study compared 
the cost-effectiveness of SCS between six Western-European countries. For several 
values of WTP, we investigated the impact of between-country differences in nine 
factors on the incremental net monetary beneﬁt (INMB). The factors were demogra-
phy, smoking prevalence, mortality, epidemiology and costs of smoking-related dis-
eases, resource use and unit costs of SCS, utility weights and discount rates. RESULTS: 
Currently, SCS is not reimbursed in The Netherlands, corresponding to a WTP of 
a 0. With a WTP below a1000, the factors most responsible for between-country dif-
ferences in INMB are resource use and unit costs of SCS and the costs of smoking-
related diseases. Utility values have little impact. At a threshold above a10,000, 
between-country differences are primarily due to different discount rates, utility 
weights and epidemiology of smoking-related diseases (incidence and mortality). Costs 
of smoking-related diseases have little impact above a20,000. At all thresholds, 
demography has little impact. CONCLUSIONS: When judging the transferability of 
a CE study to another jurisdiction, we should consider the between-country differences 
in threshold values per QALY.
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MEASURING AND MONITORING THE REAL-WORLD COST-
EFFECTIVENESS OF NEW TECHNOLOGIES IN HOSPITALS
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OBJECTIVES: Due to setting speciﬁc characteristics the economic attractiveness of 
new technologies might vary between hospitals. We compared classical and statistical 
process control (SPC) methods for measuring and monitoring the real-world cost-
effectiveness of new technologies in hospitals. METHODS: A systematic literature 
review was performed in PubMed in April 2009 to identify studies applying classical 
and SPC methods for investigating the (cost-)effectiveness of changes in inpatient       
health care processes. Both methodologies were compared using a predeﬁned set of cri-       
teria such as accuracy, ﬂexibility, informative value, suitability and user-friendliness. 
RESULTS: Classical statistical methods based on ‘time static’ (cross-sectional) statisti-
cal analysis with aggregated data are widely used. With the ability to detect statistical 
signiﬁcant differences classical methods may provide higher accuracy. They are char-
acterized by large one-time data collections to evaluate the impact of a process change 
for a pre-speciﬁed time period, limiting their ﬂexibility. SPC methods which analyze 
time series data by monitoring a process over time have been used rarely but their 
application is increasing. They combine time series analysis with a graphical represen-
tation of the data. Patterns in time series data contain important information which 
other methods reliant on averages (or other summary statistics) could mask. By provid-
ing continuous feedback SPC is capable not only of detecting the results of process 
changes earlier but also of monitoring the process sustainability. SPC can be applied 
to routine data easier as it is typically less sensitive to statistical issues. Furthermore, 
the graphical representation of the data has advantages because statistical measures 
such as P-values are often poorly understood and misinterpreted. CONCLUSIONS: 
Both methodologies are suitable for measuring the (cost)-effectiveness of changes in 
health care processes. SPC seems to be the preferred methodology under real-world 
conditions to support decision-making although it commonly does not achieve the 
accuracy of classical statistical methods.
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THE NATURE AND SCALE OF INADEQUATE REPORTING OF 
CONTINUOUS OUTCOMES FROM FOUR SYSTEMATIC REVIEWS
Singh N, Dimri S, Mahajan A, Agrawal R, Ubhadiya BS, Narvilkar P, Bhanderi M
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OBJECTIVES: Inadequate reporting of continuous outcomes is a major problem while 
performing meta-analysis. The objective of this study is to estimate the nature and 
scale of inadequate reporting of continuous outcomes. METHODS: Reporting quality 
of continuous outcomes (baseline, endpoint and change from baseline data) was ana-
lysed across four disease area reviews conducted in lipid disorder, overactive bladder, 
multiple sclerosis and rheumatoid arthritis. Reporting quality was considered inade-
quate when either number of patients analysed (N) was not reported or error term 
was missing/could not be calculated from the reported statistics. Analyses were con-
ducted using STATA 9.2. RESULTS: In total 12,236 reported outcomes across the 
four systematic reviews were included in the analysis. Inadequate reporting of continu-
ous outcomes was frequent and observed for 3912 (31.97%) outcomes. The estimate 
of inadequate reporting varied across selected reviews and ranged from 27.10% to 
45.77% in lipid disorder and overactive bladder, respectively. Of the outcomes 
reported inadequately, number of patients analysed (N) was missing for 8.82% 
whereas error term was missing or could not be calculated for 91.18% outcomes. 
When the reporting quality was analysed by the outcome type, it was observed that 
change from baseline data were often reported inadequately (49.63%) compared to 
baseline & endpoint data (25.00% and 24.51%, respectively). CONCLUSIONS: 
Inadequate reporting of continuous outcome was frequently observed among the 
selected reviews especially for the change from baseline outcomes. The results dem-
onstrated that for majority of the outcomes, the error term was either missing or could 
not be calculated from the given statistics. This inadequacy of reporting could have a 
signiﬁcant impact on the results of meta-analysis. Our results are indicative of outcome 
reporting bias which needs to be investigated further.
